Car-T cells for severe autoimmune diseases in children and young adults
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a special type of therapy called CAR-T cells, which are made from the patient's own blood cells and are designed to help control severe autoimmune diseases that haven't improved with other treatments. It is for children and young adults aged 5 to 19 with certain conditions like lupus, scleroderma, or myositis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 5 to 19 years old and willing to give consent (or have a guardian do so).
- Must have one of these autoimmune diseases: lupus, scleroderma, myositis, IgA nephropathy, or steroid-resistant nephrotic syndrome.
- Must have tried standard treatments and they didn't work well enough.
- Need adequate organ function (like heart, lungs, kidneys, and liver).
- No history of prior CAR-T therapy, and no active infections like HIV, hepatitis, or uncontrolled infections.
- Women of childbearing age must use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells, to reset the immune system in people with severe autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome. It aims to reduce disease activity and potentially improve quality of life.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.